Condition: Metastatic Melanoma · Sponsor: Abramson Cancer Center at Penn Medicine
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
This description comes directly from the study's public registry record.
Tara Mitchell, MD · 855-216-0098 · penncancertrials@emergingmed.com
Always discuss trial participation with your own doctor first.
| Lancaster General Hospital | Lancaster, Pennsylvania, United States | Recruiting |
| Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Huntsman Cancer Institute at the University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03646617